Spots Global Cancer Trial Database for aromatase inhibitor
Every month we try and update this database with for aromatase inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. | NCT06086340 | Breast Cancer | Palbociclib Aromatase Inhib... | 65 Years - | Pfizer | |
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) | NCT01050634 | Post Menopausal... | Aromasin (exeme... | - | Pfizer | |
| Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment | NCT00237198 | Postmenopausal ... | Letrozole | 20 Years - 79 Years | Novartis | |
| NEOBREADS: Neoadjuvant Breast Diet Study | NCT03822715 | Breast Cancer | Carbohydrate re... standard of car... | 18 Years - | Cedars-Sinai Medical Center | |
| Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | NCT00237211 | Postmenopausal ... | Letrozole | 20 Years - 74 Years | Novartis | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients | NCT01921296 | Sleep Initiatio... Pain | Cyclobenzaprine | 18 Years - | University of Michigan Rogel Cancer Center | |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer | NCT01491737 | Breast Cancer | Pertuzumab Trastuzumab Aromatase Inhib... Induction Chemo... | 18 Years - | Hoffmann-La Roche | |
| Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia | NCT05315011 | Breast Cancer Aromatase Inhib... | Whole-body cryo... Placebo cryothe... | 18 Years - | University Hospital, Montpellier | |
| Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer | NCT01654185 | Metastatic Brea... | AI plus Dimethy... Aromatase Inhib... | 18 Years - | Fudan University | |
| Impact of Pilates Method on Myofascial Stiffness, Cardiorespiratory Fitness and Quality of Life in Breast Cancer Women | NCT06419023 | Breast Cancer F... | supervised phys... | 30 Years - 55 Years | Poznan University of Physical Education | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors | NCT05713435 | Genitourinary S... | intravaginal la... | 18 Years - 100 Years | Universitaire Ziekenhuizen KU Leuven | |
| BREADS: Breast Adjuvant Diet Study | NCT04189263 | Breast Cancer | Carbohydrate re... standard of car... | 18 Years - | Cedars-Sinai Medical Center | |
| Aromatase Inhibitor Clinical Trial | NCT00228956 | Breast Cancer | pharmacodynamic... | 40 Years - 70 Years | National Institute of General Medical Sciences (NIGMS) | |
| Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease | NCT03865992 | Breast Cancer Joint Pain | Curcumin Placebo Nanoemulsion Quality-of-Life... Questionnaire | - | City of Hope Medical Center | |
| Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone | NCT05012644 | Metastatic Brea... | Palbociclib + a... Aromatase inhib... | - | Pfizer | |
| Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients | NCT03956875 | Breast Cancer Aromatase Inhib... Yoga Knee Pain | yoga | 20 Years - 70 Years | China Medical University Hospital | |
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | NCT05801705 | Hormone-recepto... Premenopausal B... Breast Cancer P... Ovarian Functio... | Aromatase inhib... ovarian functio... Tamoxifen toremifene | 18 Years - 60 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs | NCT04170920 | Breast Cancer DCIS | LifeExtend-AI | 18 Years - | Indiana University | |
| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00097344 | Breast Neoplasm... Neoplasms, Horm... | Atamestane Toremifene Letrozole Aromatase inhib... Estrogen recept... Hormone therapy Endocrine thera... Antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer | NCT01351844 | Breast Cancer Arthralgia | Education and e... Education and G... | 18 Years - | George Washington University | |
| Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging | NCT05700006 | Breast Neoplasm... Arthralgia Aging | Aromatase inhib... | 18 Years - | University of Michigan | |
| Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | NCT00247663 | Postmenopausal ... | Letrozole | 20 Years - 74 Years | Novartis | |
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | NCT06107673 | Breast Cancer | Dalpiciclib Aromatase inhib... Docetaxel injec... Epirubicin Hydr... Cyclophosphamid... | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer | NCT01351844 | Breast Cancer Arthralgia | Education and e... Education and G... | 18 Years - | George Washington University | |
| Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors | NCT04042870 | Breast Cancer | Joint Loosening... | 35 Years - 70 Years | AshtaYoga, LLC | |
| Study of ESR1 Mutations in Metastatic Breast Cancer | NCT02473120 | Metastatic Brea... | Determination o... | 18 Years - | Centre Henri Becquerel | |
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | NCT05801705 | Hormone-recepto... Premenopausal B... Breast Cancer P... Ovarian Functio... | Aromatase inhib... ovarian functio... Tamoxifen toremifene | 18 Years - 60 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Letrozole as a Treatment of Endometrial Cancer | NCT00997373 | Endometrial Car... | Letrozole | 40 Years - | University of California, Davis | |
| Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? | NCT00766532 | Breast Cancer Osteoporosis Osteopenia Fracture | Aromatase Inhib... | - | University of Wisconsin, Madison | |
| The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women | NCT00566553 | Breast Cancer | Grape Seed Extr... Grape Seed Extr... Grape Seed Extr... Grape Seed Extr... | 55 Years - 75 Years | Mayo Clinic | |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer | NCT02394496 | Metastatic Brea... | Fulvestrant Lapatinib Aromatase Inhib... Placebo Lapatin... | 18 Years - | Consorzio Oncotech | |
| Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | NCT03324932 | Breast Cancer | Denosumab Injec... | 20 Years - | Kyoto Prefectural University of Medicine | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | NCT04111978 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... High-grade Sero... Low-grade Serou... Ovarian Endomet... | Letrozole 2.5mg Placebo | 18 Years - | Swiss GO Trial Group | |
| Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer | NCT00171808 | Endometrial Can... | Letrozole | 18 Years - | Novartis | |
| Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings | NCT03697200 | Aromatase Inhib... Musculoskeletal... Postmenopausal ... | APA Sham APA contro... Education contr... | 18 Years - | Johns Hopkins University | |
| Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | NCT03846583 | Breast Cancer | Tucatinib Abemaciclib Trastuzumab Aromatase Inhib... | 18 Years - | Dana-Farber Cancer Institute | |
| Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor | NCT01765049 | Invasive Breast... Estrogen Recept... | - 70 Years | Seoul National University Hospital | ||
| Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy | NCT00916162 | Breast Cancer | 35 Years - | Massachusetts General Hospital | ||
| Overcoming Endocrine Resistance in Metastatic Breast Cancer | NCT02394496 | Metastatic Brea... | Fulvestrant Lapatinib Aromatase Inhib... Placebo Lapatin... | 18 Years - | Consorzio Oncotech | |
| Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00549822 | Breast Cancer | Letrozole | 18 Years - | Massachusetts General Hospital | |
| The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer | NCT01080170 | Breast Cancer | 60 Years - 75 Years | University of Pittsburgh | ||
| Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | NCT02767661 | Breast Cancer | Capecitabine Aromatase Inhib... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting | NCT02413008 | Vaginal Atrophy | estriol Placebo | - | ITF Research Pharma, S.L.U. | |
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy | NCT01016665 | Breast Cancer | Anastrozole | 40 Years - 90 Years | Federal University of São Paulo | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | NCT04762979 | Hormone Recepto... HER2-negative B... PIK3CA Mutant M... | Alpelisib Fulvestrant Aromatase inhib... | 18 Years - | Big Ten Cancer Research Consortium | |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | NCT01220128 | Neoplasms, Brea... | GSK Biologicals... Placebo Aromatase inhib... 5-Fluorouracil Carboplatin AUC Cyclophosphamid... Docetaxel Doxorubicin Epirubicin Paclitaxel Trastuzumab | 18 Years - | GlaxoSmithKline | |
| Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia | NCT05315011 | Breast Cancer Aromatase Inhib... | Whole-body cryo... Placebo cryothe... | 18 Years - | University Hospital, Montpellier | |
| Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | NCT02040857 | Breast Cancer | Palbociclib Aromatase Inhib... | 18 Years - | Dana-Farber Cancer Institute | |
| Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer | NCT00301457 | Breast Cancer | Anastrozole | 45 Years - 99 Years | Maastricht University Medical Center | |
| Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | NCT02734615 | Advanced or Met... | LSZ102 LEE011 BYL719 | 18 Years - | Novartis | |
| Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） | NCT06107673 | Breast Cancer | Dalpiciclib Aromatase inhib... Docetaxel injec... Epirubicin Hydr... Cyclophosphamid... | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone | NCT05012644 | Metastatic Brea... | Palbociclib + a... Aromatase inhib... | - | Pfizer | |
| Aromatase Inhibitors for Treatment of Uterine Leiomyomas | NCT00945360 | Symptomatic or ... | Letrozole (arom... | 50 Years - 55 Years | American University of Beirut Medical Center | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer | NCT01446159 | Hormone-sensiti... | MEDI-573 Aromatase Inhib... | 18 Years - 99 Years | MedImmune LLC | |
| Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer | NCT02166281 | Endocrine Respo... | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | ||
| Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor | NCT01765049 | Invasive Breast... Estrogen Recept... | - 70 Years | Seoul National University Hospital | ||
| Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer | NCT01814865 | Post-menopausal... | Abiraterone Ace... Prednisone Aromatase Inhib... | 18 Years - | British Columbia Cancer Agency | |
| Dendritic Cell Based Therapy for Breast Cancer Patients | NCT00935558 | Breast Cancer | DC vaccine aromatase inhib... | 18 Years - | Herlev Hospital | |
| Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea | NCT01137136 | Polymorphism CYP19 Aromatase Inhib... | - 80 Years | Samsung Medical Center | ||
| Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast | NCT04666805 | Breast Cancer | Tamoxifen Toremifene Anastrozole Letrozole Exemestane | 18 Years - 85 Years | First Hospital of China Medical University | |
| Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms | NCT03069313 | Relief of Joint... | Vitamin B12 | 18 Years - | Texas Tech University Health Sciences Center, El Paso | |
| Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea | NCT01137136 | Polymorphism CYP19 Aromatase Inhib... | - 80 Years | Samsung Medical Center | ||
| AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | NCT03959891 | Breast Cancer | Ipatasertib Fulvestrant Aromatase Inhib... Palbociclib | 18 Years - | Massachusetts General Hospital | |
| Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients | NCT01814397 | Breast Cancer Pain Arthralgia | Anastrozole exemestane letrozole | 21 Years - | University of Michigan Rogel Cancer Center | |
| Acupuncture for Stiffness of Joint Related to Aromatase Inhibitors in Patients With Early-Stage Breast Cancer | NCT05098951 | Breast Cancer Stiffness of Ha... | Acupuncture | 18 Years - 75 Years | Affiliated Hospital of Qinghai University | |
| Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | NCT00247663 | Postmenopausal ... | Letrozole | 20 Years - 74 Years | Novartis | |
| CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach) | NCT00681122 | Breast Cancer | 18 Years - | AstraZeneca | ||
| Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer | NCT01654185 | Metastatic Brea... | AI plus Dimethy... Aromatase Inhib... | 18 Years - | Fudan University | |
| The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer | NCT00097344 | Breast Neoplasm... Neoplasms, Horm... | Atamestane Toremifene Letrozole Aromatase inhib... Estrogen recept... Hormone therapy Endocrine thera... Antiestrogen th... | 18 Years - | Intarcia Therapeutics | |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer | NCT02394496 | Metastatic Brea... | Fulvestrant Lapatinib Aromatase Inhib... Placebo Lapatin... | 18 Years - | Consorzio Oncotech | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | NCT01610284 | Breast Cancer | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
